Zeimet AG - Search Results

1

Evaluation of Vav3.1 as prognostic marker in endometrial cancer.

Boesch M, Sopper S, Marth C, Fiegl H, Wiedemair A, Rössler J, Hatina J, Wolf D, Reimer D, Zeimet AG. Boesch M, et al. Among authors: zeimet ag. J Cancer Res Clin Oncol. 2018 Oct;144(10):2067-2076. doi: 10.1007/s00432-018-2725-2. Epub 2018 Aug 6. J Cancer Res Clin Oncol. 2018. PMID: 30083818 Free PMC article.

2

[Prognostic significance of tumor markers in cervix cancer].

Marth C, Zeimet AG, Fuith LC, Hetzel H, Zech S, Daxenbichler G. Marth C, et al. Among authors: zeimet ag. Gynakol Geburtshilfliche Rundsch. 1992;32 Suppl 1:114. doi: 10.1159/000271963. Gynakol Geburtshilfliche Rundsch. 1992. PMID: 1286307 Free article. German. No abstract available.

3

[The value of tumor markers in vulvar cancer].

Zeimet AG, Marth C, Abfalter E, Müller-Holzner E, Heim K, Pinzger G, Baumgartner P, Daxenbichler G, Dapunt O. Zeimet AG, et al. Gynakol Geburtshilfliche Rundsch. 1992;32 Suppl 1:28-30. doi: 10.1159/000271927. Gynakol Geburtshilfliche Rundsch. 1992. PMID: 1286338 German. No abstract available.

4

[Interferon-gamma suppresses expression of the HER-2 oncogene in ovarian cancer cells].

Marth C, Müller-Holzner E, Zeimet AG, Greiter E, Cronauer MV, Doppler W, Eibl B, Hynes NE, Daxenbichler G. Marth C, et al. Among authors: zeimet ag. Gynakol Geburtshilfliche Rundsch. 1992;32(1):31-4. doi: 10.1159/000271830. Gynakol Geburtshilfliche Rundsch. 1992. PMID: 1355379 German.

5

Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells.

Marth C, Lang T, Cronauer MV, Doppler W, Zeimet AG, Bachmair F, Ullrich A, Daxenbichler G. Marth C, et al. Among authors: zeimet ag. Int J Cancer. 1992 Sep 9;52(2):311-6. doi: 10.1002/ijc.2910520226. Int J Cancer. 1992. PMID: 1355758

6

Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells.

Marth C, Zeimet AG, Böck G, Daxenbichler G. Marth C, et al. Among authors: zeimet ag. Eur J Cancer. 1992;28A(12):2002-6. doi: 10.1016/0959-8049(92)90248-z. Eur J Cancer. 1992. PMID: 1419298

7

Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells.

Marth C, Müller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppler W, Eibl B, Hynes NE, Daxenbichler G. Marth C, et al. Among authors: zeimet ag. Cancer Res. 1990 Nov 1;50(21):7037-41. Cancer Res. 1990. PMID: 2119884

8

Distribution of CA 125 in placental tissues.

Fuith LC, Müller-Holzner E, Marth C, Perkmann E, Zeimet A, Daxenbichler G. Fuith LC, et al. Int J Biol Markers. 1989 Apr-Jun;4(2):78-80. doi: 10.1177/172460088900400203. Int J Biol Markers. 1989. PMID: 2768891

9

Increased production of immune activation marker neopterin by colony-stimulating factors in gynecological cancer patients.

Marth C, Weiss G, Koza A, Reibnegger G, Daxenbichler G, Zeimet AG, Fuchs D, Wachter H, Dapunt O. Marth C, et al. Among authors: zeimet ag. Int J Cancer. 1994 Jul 1;58(1):20-3. doi: 10.1002/ijc.2910580105. Int J Cancer. 1994. PMID: 7516925 Clinical Trial.

10

Prognostic value of CD44 splice variant expression in ovarian cancer.

Uhl-Steidl M, Müller-Holzner E, Zeimet AG, Adolf GR, Daxenbichler G, Marth C, Dapunt O. Uhl-Steidl M, et al. Among authors: zeimet ag. Oncology. 1995 Sep-Oct;52(5):400-6. doi: 10.1159/000227497. Oncology. 1995. PMID: 7543667

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

202 results

Search Page